MCID: PRG003
MIFTS: 37

Progesterone-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Progesterone-Receptor Negative Breast Cancer

MalaCards integrated aliases for Progesterone-Receptor Negative Breast Cancer:

Name: Progesterone-Receptor Negative Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060078

Summaries for Progesterone-Receptor Negative Breast Cancer

MalaCards based summary : Progesterone-Receptor Negative Breast Cancer is related to breast cancer and scirrhous adenocarcinoma. An important gene associated with Progesterone-Receptor Negative Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gastric cancer and Proteoglycans in cancer. The drugs Bevacizumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, t cells and brain, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Related Diseases for Progesterone-Receptor Negative Breast Cancer

Diseases in the Progesterone-Receptor Positive Breast Cancer family:

Progesterone-Receptor Negative Breast Cancer

Diseases related to Progesterone-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 breast cancer 10.4
2 scirrhous adenocarcinoma 10.2 ERBB2 PGR
3 breast apocrine carcinoma 10.2 ERBB2 PGR
4 glassy cell carcinoma of the cervix 10.2 ERBB2 PGR
5 breast mucoepidermoid carcinoma 10.2 ERBB2 PGR
6 breast metaplastic carcinoma 10.2 ERBB2 PGR
7 breast medullary carcinoma 10.2 ERBB2 PGR
8 progesterone-receptor positive breast cancer 10.2 ERBB2 PGR
9 apocrine adenocarcinoma 10.2 ERBB2 PGR
10 uterine body mixed cancer 10.2 ERBB2 PGR
11 uterine corpus cancer 10.2 ERBB2 PGR
12 breast benign neoplasm 10.2 ERBB2 PGR
13 thoracic benign neoplasm 10.2 ERBB2 PGR
14 mixed cell type cancer 10.1 ERBB2 PGR
15 breast secretory carcinoma 10.1 ERBB2 PGR
16 bilateral breast cancer 10.1 ERBB2 PGR
17 breast papillary carcinoma 10.1 ERBB2 PGR
18 fallopian tube carcinoma 10.1 ERBB2 PGR
19 papillary adenocarcinoma 10.1 ERBB2 PGR
20 sweat gland cancer 10.1 ERBB2 PGR
21 estrogen-receptor negative breast cancer 10.1 ERBB2 PGR
22 breast fibroadenoma 10.1 ERBB2 PGR
23 female breast cancer 10.0 ERBB2 PGR
24 serous cystadenocarcinoma 10.0 ERBB2 PGR
25 cystadenocarcinoma 10.0 ERBB2 PGR
26 sporadic breast cancer 10.0 ERBB2 PGR
27 ovarian serous cystadenocarcinoma 10.0 ERBB2 PGR
28 breast disease 9.9 ERBB2 PGR
29 peritoneal mesothelioma 9.9 EGFR PGR
30 papillary carcinoma 9.9 ERBB2 PGR
31 breast intraductal proliferative lesion 9.8 EGFR ERBB2
32 acneiform dermatitis 9.7 EGFR ERBB2
33 adenosquamous cell lung carcinoma 9.7 EGFR ERBB2
34 hidradenocarcinoma 9.7 EGFR ERBB2
35 gallbladder adenocarcinoma 9.7 EGFR ERBB2
36 small intestinal adenocarcinoma 9.7 EGFR ERBB2
37 helicobacter pylori infection 9.6 EGFR TLR4
38 exanthem 9.6 EGFR ERBB2
39 cervical adenocarcinoma 9.6 EGFR ERBB2
40 salivary gland cancer 9.6 EGFR ERBB2
41 oral cavity cancer 9.5 EGFR ERBB2
42 respiratory system cancer 9.5 EGFR ERBB2
43 mucoepidermoid carcinoma 9.4 EGFR ERBB2
44 gastrointestinal system cancer 9.3 EGFR ERBB2
45 intracystic papillary adenoma 9.3 EGFR ERBB2 PGR
46 breast scirrhous carcinoma 9.3 EGFR ERBB2 PGR
47 oncocytic breast carcinoma 9.3 EGFR ERBB2 PGR
48 breast adenoid cystic carcinoma 9.3 EGFR ERBB2 PGR
49 breast squamous cell carcinoma 9.3 EGFR ERBB2 PGR
50 microglandular adenosis 9.3 EGFR ERBB2 PGR

Graphical network of the top 20 diseases related to Progesterone-Receptor Negative Breast Cancer:



Diseases related to Progesterone-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Progesterone-Receptor Negative Breast Cancer

GenomeRNAi Phenotypes related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.8 EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-3 8.8 EGFR

MGI Mouse Phenotypes related to Progesterone-Receptor Negative Breast Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.56 EGFR ERBB2 PGR TLR4
2 limbs/digits/tail MP:0005371 9.46 EGFR ERBB2 PGR TLR4
3 muscle MP:0005369 9.26 EGFR ERBB2 PGR TLR4
4 neoplasm MP:0002006 8.92 EGFR ERBB2 PGR TLR4

Drugs & Therapeutics for Progesterone-Receptor Negative Breast Cancer

Drugs for Progesterone-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
5
Fluorouracil Approved Phase 3 51-21-8 3385
6
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
7
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
8
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
9
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3 33069-62-4 36314
10
Goserelin Approved Phase 3 65807-02-5 47725 5311128
11
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
12
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
13
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
14
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
17
Doxil Approved June 1999 Phase 3,Phase 2 31703
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Angiogenesis Inhibitors Phase 3,Phase 2
20 Angiogenesis Modulating Agents Phase 3,Phase 2
21 Anti-Bacterial Agents Phase 3,Phase 2
22 Antibiotics, Antitubercular Phase 3,Phase 2
23 Antimetabolites Phase 3,Phase 2
24 Antimetabolites, Antineoplastic Phase 3,Phase 2
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
26 Antirheumatic Agents Phase 3,Phase 2
27 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
29 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
31 Immunosuppressive Agents Phase 3,Phase 2
32 Progestins Phase 3,Phase 2,Phase 1,Not Applicable
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
34 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3
35 Anti-Infective Agents Phase 2, Phase 3
36 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
37 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
38 Antiviral Agents Phase 2, Phase 3
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2
40 Dermatologic Agents Phase 3,Phase 2
41 Folic Acid Antagonists Phase 3,Phase 2
42 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
43 Vitamin B Complex Phase 3,Phase 2
44 triamcinolone acetonide Phase 3
45 Triamcinolone diacetate Phase 3
46 Triamcinolone hexacetonide Phase 3
47 Folate Nutraceutical Phase 3,Phase 2
48 Vitamin B9 Nutraceutical Phase 3,Phase 2
49
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
50
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed NCT01881230 Phase 2, Phase 3 nab-Paclitaxel;Carboplatin;Gemcitabine
3 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
4 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
5 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Completed NCT00022516 Phase 3 Cyclophosphamide;Methotrexate
6 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3
7 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
8 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
9 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
10 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Unknown status NCT01037790 Phase 2 PD-0332991
11 Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer Completed NCT00577122 Phase 2 Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
12 Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Completed NCT00559507 Phase 2 saracatinib
13 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
14 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
15 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Completed NCT01105312 Phase 1, Phase 2 letrozole;panobinostat
16 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
17 Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Completed NCT00834678 Phase 1, Phase 2 bendamustine;erlotinib;Maintenance erlotinib
18 Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery Completed NCT00424203 Phase 2 AC regimen;cyclophosphamide;doxorubicin hydrochloride
19 Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer Recruiting NCT02315196 Phase 2 pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
20 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Active, not recruiting NCT00733408 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
21 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Active, not recruiting NCT01818063 Phase 2 Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
22 Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Active, not recruiting NCT01372579 Phase 2 eribulin mesylate;carboplatin
23 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting NCT01463072 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
24 Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Active, not recruiting NCT01147016 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
25 Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery Terminated NCT01234532 Phase 2 entinostat;anastrozole
26 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer Terminated NCT01151449 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
27 A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer Withdrawn NCT00252811 Phase 2 Gefitinib
28 Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer Withdrawn NCT01100489 Phase 2
29 Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery Withdrawn NCT01612910 Phase 2 oral microencapsulated diindolylmethane
30 Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
31 Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer Completed NCT01104259 Phase 1 veliparib;cisplatin;vinorelbine tartrate
32 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
33 Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
34 Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32 Unknown status NCT01666171 metformin hydrochloride
35 Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer Completed NCT00870168 Not Applicable chemotherapy
36 F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Completed NCT00602043 Not Applicable
37 Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer Completed NCT00755313 aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride
38 Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer Completed NCT00115505
39 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases Completed NCT00072293 Not Applicable
40 Assessment of Candidate Protein Expression in Breast Cancer Specimens Recruiting NCT00918892

Search NIH Clinical Center for Progesterone-Receptor Negative Breast Cancer

Genetic Tests for Progesterone-Receptor Negative Breast Cancer

Anatomical Context for Progesterone-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Progesterone-Receptor Negative Breast Cancer:

41
Breast, T Cells, Brain, Lymph Node, Bone

Publications for Progesterone-Receptor Negative Breast Cancer

Articles related to Progesterone-Receptor Negative Breast Cancer:

(show all 11)
# Title Authors Year
1
<i>SF3B1</i> mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients. ( 29383138 )
2017
2
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. ( 28875243 )
2017
3
Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer. ( 27314854 )
2016
4
Mediation of Racial and Ethnic Disparities in Estrogen/Progesterone Receptor-Negative Breast Cancer by Socioeconomic Position and Reproductive Factors. ( 27076668 )
2016
5
Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. ( 26392082 )
2015
6
Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry. ( 24548865 )
2014
7
A model of spontaneous mouse mammary tumor for human estrogen receptor- and progesterone receptor-negative breast cancer. ( 25230850 )
2014
8
Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. ( 20647407 )
2010
9
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. ( 16145046 )
2005
10
Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. ( 15041725 )
2004
11
Induction of progesterone receptor in an estrogen, progesterone receptor-negative breast cancer cell line. ( 3702420 )
1986

Variations for Progesterone-Receptor Negative Breast Cancer

Expression for Progesterone-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Negative Breast Cancer.

Pathways for Progesterone-Receptor Negative Breast Cancer

Pathways related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 EGFR ERBB2 PGR
2 11.74 EGFR ERBB2 TLR4
3
Show member pathways
11.72 EGFR ERBB2
4
Show member pathways
11.52 EGFR ERBB2
5
Show member pathways
11.43 EGFR ERBB2 TLR4
6 11.39 EGFR ERBB2
7 11.37 EGFR ERBB2
8 11.33 EGFR ERBB2
9 11.29 EGFR ERBB2
10 11.18 EGFR ERBB2
11
Show member pathways
11.17 EGFR ERBB2 PGR
12 11.06 EGFR ERBB2
13 10.86 EGFR ERBB2
14 10.8 EGFR ERBB2
15 10.8 EGFR ERBB2 TLR4

GO Terms for Progesterone-Receptor Negative Breast Cancer

Cellular components related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.43 EGFR ERBB2 TLR4
2 basal plasma membrane GO:0009925 9.16 EGFR ERBB2
3 endosome membrane GO:0010008 9.13 EGFR ERBB2 TLR4
4 receptor complex GO:0043235 8.8 EGFR ERBB2 TLR4

Biological processes related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol phosphorylation GO:0046854 9.57 EGFR ERBB2
2 wound healing GO:0042060 9.56 EGFR ERBB2
3 positive regulation of cell growth GO:0030307 9.55 EGFR ERBB2
4 cellular response to mechanical stimulus GO:0071260 9.54 EGFR TLR4
5 positive regulation of inflammatory response GO:0050729 9.52 EGFR TLR4
6 signal transduction by protein phosphorylation GO:0023014 9.51 EGFR ERBB2
7 positive regulation of kinase activity GO:0033674 9.49 EGFR ERBB2
8 positive regulation of MAP kinase activity GO:0043406 9.48 EGFR ERBB2
9 positive regulation of epithelial cell proliferation GO:0050679 9.46 EGFR ERBB2
10 cellular response to growth factor stimulus GO:0071363 9.43 EGFR ERBB2
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.4 EGFR TLR4
12 cellular response to epidermal growth factor stimulus GO:0071364 9.37 EGFR ERBB2
13 ERBB2 signaling pathway GO:0038128 9.32 EGFR ERBB2
14 regulation of cell motility GO:2000145 9.26 EGFR ERBB2
15 regulation of ERK1 and ERK2 cascade GO:0070372 9.16 EGFR ERBB2
16 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.13 EGFR ERBB2 TLR4
17 negative regulation of ERBB signaling pathway GO:1901185 8.62 EGFR ERBB2

Molecular functions related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.58 EGFR ERBB2 TLR4
2 MAP kinase kinase kinase activity GO:0004709 9.43 EGFR ERBB2
3 protein phosphatase binding GO:0019903 9.37 EGFR ERBB2
4 mitogen-activated protein kinase kinase binding GO:0031434 9.32 EGFR ERBB2
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGFR ERBB2
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.16 EGFR ERBB2
7 transmembrane signaling receptor activity GO:0004888 9.13 EGFR ERBB2 TLR4
8 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.62 EGFR ERBB2

Sources for Progesterone-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....